


# Keystone Symposia: Triglycerides and Triglyceride-Rich Particles in Health and Disease

January 9–14, 2010 • Big Sky Resort • Big Sky, Montana • USA  
Scientific Organizers: Robert H. Eckel, Ira J. Goldberg and Ruth McPherson

## PROGRAM FACULTY & TALKS

- Nada A. Abumrad**, Washington University, USA  
*FFA Uptake and Intracellular Trafficking*
- Sudha Biddinger**, Harvard University, USA  
*Hepatic Insulin Resistance, TG and Atherosclerosis*
- B. Greg Brown**, University of Washington School of Medicine, USA  
*Niacin Therapy and Atherosclerosis*
- John Chapman**, INSERM (U.939), France  
*CETP Inhibitors and TG-Rich Lipoproteins*
- Dong Cheng**, Bristol-Myers Squibb Company, USA  
*Are DGAT Inhibitors a Target for Triglyceride Lowering?*
- Rosalind A. Coleman**, University of North Carolina at Chapel Hill, USA  
*Metabolic Channeling and Control of Fatty Acid Metabolism*
- Michael H. Criqui**, University of California, San Diego, USA  
*Population Studies of TG and ASCVD*
- Rosanne Crooke**, ISIS Pharmaceuticals, USA  
*Development of Novel Antisense Inhibitors for the Treatment of Hypertriglyceridemia*
- Robert H. Eckel**, University of Colorado Denver, Anschutz Medical Campus, USA  
*Triglycerides in Health and Disease*
- Marshall B. Elam**, Veterans Affairs Medical Center Memphis, University of Tennessee, USA  
*Fibrates and CVD Risk Reduction*
- Mark D. Erion**, Metabasis Therapeutics, Inc., USA  
*Thyroid Hormone Receptor- $\beta$  Agonists and TG Lowering*
- Edward Allen Fisher**, New York University School of Medicine, USA  
*Omega-3 Fatty Acids and Lipoprotein Metabolism: Mechanistic Basis for Their Clinical Effects*
- Keith N. Frayn**, University of Oxford, UK  
*Triglyceride Uptake into Human Adipose Tissue*
- Susan K. Fried**, Boston Medical Center, USA  
*Adipocytokines and Lipolysis*
- Henry N. Ginsberg\***, Columbia University College of Physicians and Surgeons, USA  
*Increased Assembly and Secretion of Triglyceride-Rich Lipoproteins in Insulin Resistance: Greasing the Path to Atherosclerosis*
- Ira J. Goldberg**, Columbia University, USA  
*LPL Mediated Uptake*
- M. Mahmood Hussain**, SUNY Downstate Medical Center, USA  
*MTP and Chylomicron Production*
- Samuel Klein**, Washington University School of Medicine, USA  
*Therapeutic Implications of the Hormonal and Nutritional Regulation of Adipose Tissue Lipolysis and Hepatic Triglyceride Metabolism*
- Gary F. Lewis**, Toronto General Hospital, Canada  
*Apo B Production - Human Gut and Liver*
- Ruth McPherson**, University of Ottawa Heart Institute, Canada  
*Genetic Disorders of TG Metabolism*
- Børge Nordestgaard**, University of Copenhagen, Denmark  
*Non-Fasting TGs and CVD Risk*
- James Mukasa Ntambi**, University of Wisconsin-Madison, USA  
*SCD-1*
- Elizabeth J. Parks**, University of Texas Southwestern Medical Center, USA  
*Dietary Influences on TG-Rich Lipoprotein Production*
- Jack Rutledge**, University of California, Davis, USA  
*TG-Rich Lipoproteins and Inflammation and Anti-Inflammation*
- Frank Sacks**, Harvard School of Public Health, USA  
*ApoCIII*
- Clay F. Semenkovich**, Washington University School of Medicine, USA  
*Lipids and Stress Responses in the Evolution of Atherosclerosis*
- Alan R. Shuldiner**, University of Maryland School of Medicine, USA  
*Genome-Wide Studies of Serum Lipids: Lessons from the Old Order Amish*
- Bart Staels**, Institut Pasteur de Lille, University of Lille 2, Inserm U545, France  
*Transcription Factors and the Therapeutic Regulation of TG Production*
- Stephen G. Young**, University of California, Los Angeles, USA  
*An Endothelial Cell Protein Required for the Lipolytic Processing of Triglyceride-Rich Lipoproteins*
- Rudolf Zechner**, University of Graz, Austria  
*Hormonal Control of Intracellular Lipolysis*

\*Keynote speaker. Program subject to change. Current as of September 8, 2009



*Triglycerides are important storage molecules that play important roles in lipid and lipoprotein metabolism, insulin action, energy balance and atherosclerosis. The purpose of this meeting will be to critically examine the broad spectrum of triglyceride biology from the molecular biology of triglyceride biosynthesis in the liver and intestine to lipoprotein assembly and secretion to lipid fuel partitioning to adipose tissue, muscle and the liver. A discussion of the regulation of free fatty acid flux from adipose tissue to the liver by insulin and pro- and anti-inflammatory cytokines will precede a detailed coverage of chylomicron and VLDL transport, intravascular lipolysis and tissue-specific lipid partitioning. A transition to the science and medicine of triglycerides will then occur with expected updates on the understanding of the genetic basis of disorders of triglyceride-rich lipoprotein metabolism and the pathogenesis of atherosclerosis that relate specifically to circulating triglyceride-rich particles. The clinical relevance of hypertriglyceridemia, new insights into the mechanisms of pharmacological treatment of hypertriglyceridemia and clinical trial evidence pro and con that triglyceride lowering reduces cardiovascular disease risk will follow. The meeting should attract basic, clinical and population scientists from academia and industry, and will deal with the many issues that remain unclear or controversial surrounding triglycerides and triglyceride-rich particles in health and disease.*

## PROGRAM PLENARY SESSIONS:

- Molecular/Cell Biology and Physiology of Triglyceride Synthesis and TG-Rich Lipoprotein Assembly and Secretion
- Regulation of Lipolysis in Man and Rodents
- Chylomicron and VLDL Transport, Lipolysis and Tissue-Specific Lipid Partitioning
- Genetics and Pathophysiology of Disorders of TG-Rich Lipoprotein Metabolism
- TG-Rich Lipoproteins and Mechanisms of Atherosclerosis
- Population Science on the Relationship between TG-Rich Lipoproteins and ASCVD
- Therapeutics of Hypertriglyceridemia
- Clinical Trials of Triglyceride Lowering and Outcomes

## DEADLINES:

Abstract & Scholarship: September 15, 2009  
Late-Breaking Abstract: October 12, 2009  
Early Registration: November 9, 2009

[www.keystonesymposia.org/10A3](http://www.keystonesymposia.org/10A3)

**KEYSTONE SYMPOSIA™**  
on Molecular and Cellular Biology  
*Accelerating Life Science Discovery*

PO Box 1630 • Silverthorne, CO 80498 • USA  
[www.keystonesymposia.org](http://www.keystonesymposia.org) • 1-800-253-0685 • 1-970-262-1230